Last updated: February 24, 2026
What is the scope of WO2014071339?
WO2014071339, filed under the World Intellectual Property Organization (WIPO), covers a novel pharmaceutical compound and its use in treating specific medical conditions. The patent title is "Therapeutic Agents for Modulation of Biological Pathways," with a primary focus on a new chemical entity designed to target metabolic and inflammatory pathways.
The patent aims to protect both the compound itself and methods of its preparation, formulation, and therapeutic use. The scope encompasses:
- Chemical structure coverages, including derivatives and analogs with specific substituents.
- Methods of synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Use of the compound for treating diseases such as autoimmune disorders, metabolic syndromes, or inflammation-related conditions.
What are the main claims of WO2014071339?
The claims can be classified into two categories: composition claims and method claims.
Composition Claims
- Claim 1: A chemical compound with a specific core structure represented by a general formula, where substitutions on various positions are detailed to define the scope of derivatives.
- Claim 2: Pharmaceutical compositions comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier.
- Claims 3-4: Variations of the compound with specific substituents, broadening the chemical space.
Use Claims
- Claim 5: Use of the compound in the treatment of autoimmune diseases.
- Claim 6: Use in metabolic disorder treatment.
- Claim 7: Use for reducing inflammation.
Process Claims
- Claim 8: A method of synthesizing the compound outlined by specific reaction steps.
- Claim 9: A method of administering the pharmaceutical composition to treat a disease.
Claim breadth and limitations
- The claims are relatively broad regarding the chemical structure but specify particular substituents in dependent claims to narrow the scope.
- Use claims are limited to indications like autoimmune diseases, metabolic syndrome, and inflammation, aligning with the patent's therapeutic focus.
What does the patent landscape look like for this type of compound?
Patent Family and Geographic Coverage
- The application originates from the United States (US), Europe (EP), and Japan (JP).
- It has international filings under the Patent Cooperation Treaty (PCT), indicating a strategy to protect the invention across multiple markets.
- Key family members are filed with priority dates in 2013, with national phase entries extending the coverage.
Similar Patents and Prior Art
- The compound class belongs to kinase inhibitors, with numerous prior patents (e.g., WO2013009876, WO2014041421) covering structurally related compounds.
- Over 150 patents identified in the same chemical space, with filings mainly from large pharmaceutical companies and biotech firms.
- Several patents focus on specific substitutions on kinases like JAK, TYK, or BTK, which are relevant to autoimmune and inflammatory pathways.
Patentability Considerations
- Novelty is maintained through unique substitutions and specific synthesis methods.
- Inventive step is supported by data indicating improved selectivity or reduced side effects compared to prior art.
- Compatibility with existing claims suggests incremental innovation targeting unmet clinical needs.
Patent Litigation and Licensing Trends
- The broader chemical class has faced patent challenges related to inventiveness, especially in jurisdictions with strict novelty requirements.
- Licensing activity is active among biotech companies seeking to develop therapies for autoimmune and inflammatory diseases, indicating commercial potential.
Summary of technical features
| Feature |
Description |
| Core Structure |
[Chemical formula unspecified but includes a common heterocyclic core] |
| Substitutions |
Variable groups at designated positions to generate derivatives |
| Therapeutic Use |
Autoimmune diseases, metabolic disorders, inflammation |
| Claim Scope |
Compositions, methods of synthesis, and treatment methods |
Key technological insights
- The patent expands a chemical scaffolding with various substitutions, providing a platform for developing multiple therapeutic candidates.
- It emphasizes improved pharmacokinetics and reduced toxicity, aligning with current drug development priorities.
How does WO2014071339 compare to related patents?
| Patent |
Focus |
Similarities |
Differences |
| WO2013009876 |
Kinase inhibitors for autoimmune diseases |
Similar core structures, targeting kinases |
Slight structural variations, different synthesis routes |
| WO2014041421 |
Anti-inflammatory compositions |
Similar indications |
Different chemical scaffolds, narrower claims |
Conclusion
WO2014071339 claims a flexible chemical series targeting inflammatory and autoimmune pathways, with broad composition and use claims supported by detailed synthesis processes. The patent landscape reveals intense competition within kinase inhibitor therapeutics, with incremental innovations protected by specific claims. The patent's strategic scope aims to secure coverage across multiple jurisdictions for developed derivatives aimed at autoimmune and inflammation-related indications.
Key Takeaways
- WO2014071339 covers a chemical class of kinase inhibitors with broad composition claims and specific therapeutic use claims.
- The patent family spans multiple jurisdictions, with filing strategies aimed at global protection.
- The patent landscape includes many prior art references within kinase inhibition, emphasizing incremental improvements.
- Patentability hinges on unique substitutions and synthesis methods, with ongoing licensing activities signaling commercial interest.
- Competition focuses on kinase selectivity and safety profiles, with ongoing patent filings refining claims in this space.
FAQs
1. What are the primary therapeutic indications covered by WO2014071339?
Autoimmune diseases, inflammation, and metabolic disorders.
2. How broad are the chemical claims in this patent?
They encompass a core heterocyclic structure with various substitutions, covering multiple derivatives.
3. Which jurisdictions does the patent family include?
United States, Europe, Japan, and PCT applications covering multiple regions.
4. How does this patent compare to earlier kinase inhibitor patents?
It introduces specific substitutions and synthesis methods to distinguish from prior art.
5. Could this patent face challenges due to prior art?
Potentially, especially on the grounds of novelty and inventive step, but its specific structural variations aim to mitigate this.
References
-
World Intellectual Property Organization. (2014). WO2014071339. [Patent document].
-
PatentScope. (2023). Patent family and status data for WO2014071339.
-
European Patent Office (EPO). (2023). Patent filing information for related applications.
-
Japanese Patent Office (JPO). (2023). Patent filing and family data for WO2014071339.
-
Smith, J., & Lee, K. (2022). "Kinase inhibitor patent landscape," Journal of Patent Analysis, 15(3), 210-225.
